07-24-06

Attorney Docket No.: 10429.204-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Festersen et al

Confirmation No: TBA

Serial No.: 10/583,676

Group Art Unit: TBA

Filed: June 19, 2006

Examiner: TBA

For: Mashing Process

INFORMATION DISCLOSURE STATEMENT (IDS) UNDER 37 CFR 1.97(b)

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which may be material to the patentability of this application and with respect to which there may be a duty to disclose. While the references may be material under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are prior art. The filing of this IDS shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO/SB/08A, which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is enclosed.

This IDS is being filed **within** three months of the filing date of a national application or date of entry into the national stage of an international application, or **before** the mailing date of a first Office action on the merits, or **before** the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due.

Respectfully submitted,

Date: July 21, 2006

Jason J. Garbell, Reg. No. 44,116 Novozymes North America, Inc. 500 Fifth Avenue, Suite 1600 New York, NY 10110

(212)840-0097

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMME!
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| Substitute for form 1449A/PTO | Complete if Known | 10/583.676 **Application Number** 10/583,676 INFORMATION DISCLOSURE Filing Date June 19, 2006 First Named Inventor Festersen et al STATEMENT BY APPLICANT Art Unit TBA (use as many sheets as necessary) **Examiner Name** TBA Sheet 2 **Attorney Docket Number** of 10429.204-US

U.S PATENT DOCUMENTS						
Examiner Initials	Cite No. 1	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		US 4,238,345	12-09-1980	Guilbert C. C		
		US2005/0054071	03-10-2005	Udagawa et al		
		US2002/164399	11-07-2002	Mogen		
			-			
						
	-					

FOREIGN PATENT DOCUMENTS						
Cite No. 1	Foreign Patent Document Country Code 3 – Number 4 – Kind Code 5 (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т 6	
	WO 97/27292	07-31-1997	Novo Nordisk A/S			
	WO 02/074895	09-26-2002	Novozymes A/S			
	WO 97/27291	07-31-1997	Novo Nordisk A/S			
	WO 03/062409	07-31-2003	Roche Vitamins			
ļ						
-						
<u> </u>						
	Cite No. 1	Foreign Patent Document Cite No. 1 Country Code 3 – Number 4 – Kind Code 5 (if known) WO 97/27292 WO 02/074895 WO 97/27291	Foreign Patent Document Publication Date MM-DD-YYYY WO 97/27292 07-31-1997 WO 97/27291 07-31-1997 WO 97/27291 07-31-1997 O7-31-1997 O7-31-1	Foreign Patent Document Publication Date Name of Patentee or	Foreign Patent Document Publication Date Name of Patentee or Where Relevant Passages or Relevant Figures Appear	

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner of Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at <u>www.uspto.gov</u> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

			ons are required to r	espond to a collection of information unles			
Substitute for	Substitute for form 1449A/PTO			Compl	Complete if Known		
				Application Number	10/583,676		
INFORMATION DISCLOSURE				Filing Date	June 19, 2006		
	STATEMEN	IT BY APPLIC	ANT	First Named Inventor	Festersen et al		
		y sheets as necessa		Art Unit	TBA		
•				Examiner Name	TBA		
Sheet	2	of	2	Attorney Docket Number	10429.204-US		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner's Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²		
	-				
[Constitute]	_ !	Date			
Examiner		Date			

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner of Patents, Washington, DC 20231.

Examiner Date
Signature Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

IN THE UNITED STATED DESIGNATED/ELECTED OFFICE (DO/EO/US)

INTERNATIONAL APPLICATION NO.: PCT/DK2004/000880

INTERNATIONAL FILING DATE: December 17, 2004

PRIORITY DATE: December 19, 2003

TITLE: Mashing Process

APPLICANT(S) FOR RO/US: Festersen et al

EXPRESS MAIL CERTIFICATE

Mail Stop PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Express Mail Label No. 876363041 US

Date of Deposit: July 21, 2006

I hereby certify that the following attached papers or fee

- 1. Information Disclosure Statement
- Form PTO/SB/08A
- 3. Copy of References

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 C.F.R. 1.10 on the date indicated above and is addressed to the address indicated above.

Lourdes Ayala

(Name of person mailing paper(s) or fee)

Signature of person mailing paper(s) or fee)

Mailing Address: Novozymes North America, Inc. 500 Fifth Avenue, Suite 1600 New York, NY 10110 (212) 840-0097